Erschienen in:
01.09.2013 | Original Article
Clinical and microbiological changes after minimally invasive therapeutic approaches in intrabony defects: a 12-month follow-up
verfasst von:
Fernanda V. Ribeiro, Renato C. V. Casarin, Maria A. G. Palma, Francisco H. N. Júnior, Enilson A. Sallum, Márcio Z. Casati
Erschienen in:
Clinical Oral Investigations
|
Ausgabe 7/2013
Einloggen, um Zugang zu erhalten
Abstract
Objectives
This 12-month randomized, controlled trial evaluated the clinical effects and microbiological changes of minimally invasive nonsurgical and surgical approaches for the therapy of intrabony defects.
Materials and methods
Twenty-nine subjects with intrabony defects in single-rooted tooth were randomly assigned to; (1) minimally invasive nonsurgical technique (MINST) or (2) minimally invasive surgical technique (MIST). Quantities of Aggregatibacter actinomycetemcomitans, Tannerella forsythia, and Porphyromonas gingivalis, determined by using real-time PCR, were evaluated at baseline, 3, 6, and 12 months after the treatments. Clinical recordings—probing depth (PD), position of the gingival margin (PGM), and relative clinical attachment level (RCAL)—were obtained at baseline and 12 months post-therapy. The primary outcome variable of the study was RCAL.
Results
Both treatment modalities resulted in an improvement in all clinical recordings, with significant PD reductions (p < 0.05), RCAL gains (p < 0.05), and no change in the PGM (p > 0.05) after 12 months in both MINST and MIST groups. No clinical differences were observed between groups (p > 0.05). Regarding the microbiological outcomes, at the re-examinations, a significant decrease was observed for T. forsythia and P. gingivalis when compared with baseline (p < 0.05) for both treatments. The amount of A. actinomycetemcomitans did not reduced decrease throughout the study (p > 0.05). Intergroup differences in the microbiological assay were not found at any time point (p > 0.05).
Conclusions
Both MINST and MIST provided comparable clinical results and microbiological changes in the treatment of intrabony defects over 12 months follow-up.
Clinical relevance
This randomized, controlled, parallel trial revealed that both therapeutic modalities may promote clinical and microbiological benefits at 12 months post-therapy.